Medison Pharma
10 Hashiloach St, Petah Tikva, Central District, 4951443, Israel
Overview
Medison is a pharmaceutical company. They provide therapeutic products for biotech and pharmaceutical companies. They provide products in the fields of pharmaceuticals, medical devices, and diagnostic products. They help companies save and improve the lives of patients suffering from diseases.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 3
Sector focus
- Biotechnology
- Health Care
- Medical Device
- Therapeutics
Investment portfolio
- Keros Therapeutics
Participated · Series B · Jan 2019
Keros Therapeutics is a Lexington, MA–based company discovering and developing novel proprietary therapeutics for rare and ultra-rare neuromuscular diseases. Its two lead programs include a small-molecule ALK2 inhibitor program for fibrodysplasia ossificans progressiva (FOP) and a second program targeting other rare neuromuscular disorders. The ALK2 program, licensed from Massachusetts General Hospital and the NIH’s NCATS, has advanced through preclinical safety studies and was projected to enter Phase 1 SAD/MAD studies in H1 2019. Keros intends to advance both programs from preclinical validation through clinical proof-of-concept and into Phase II trials. The company recently completed a $23m Series B, bringing total venture funding to $34m to date. Leadership is headed by President and CEO Jasbir S. Seehra, and the company added Dr. Zafrira Avnur to its board as part of the financing announcement.